Financial Performance - The company reported a net loss of $3,446,624 for the three months ended December 31, 2023, compared to a net loss of $3,822,859 for the same period in 2022, indicating an improvement of about 9.8%[12]. - Basic and diluted loss per share improved from $(0.08) in Q4 2022 to $(0.04) in Q4 2023[12]. - The company generated net cash used in operating activities of $3,392,647 for the three months ended December 31, 2023, compared to $2,917,417 for the same period in 2022, indicating an increase in cash outflow of about 16.3%[16]. - The company anticipates recording losses from operations for the foreseeable future and will need to raise additional funds to support its operations[24]. - The company has an accumulated deficit of $125,351,000 as of December 31, 2023[163]. Assets and Liabilities - Total current assets decreased from $8,023,716 as of September 30, 2023, to $4,821,477 as of December 31, 2023, representing a decline of approximately 40.5%[8]. - The company had total liabilities of $3,787,220 as of December 31, 2023, down from $4,521,985 as of September 30, 2023, representing a decrease of about 16.3%[8]. - Total stockholders' equity decreased from $3,743,912 as of September 30, 2023, to $1,225,889 as of December 31, 2023, a decline of approximately 67.3%[8]. - Cash and cash equivalents decreased from $8,023,716 at the beginning of the period to $4,821,477, a decrease of approximately 40.5%[8]. - Current liabilities decreased from $4,521,985 to $3,787,220, a reduction of about 16.3%[8]. Research and Development - Research and development expenses for the three months ended December 31, 2023, were $1,486,388, down from $1,743,051 in the same period of 2022, reflecting a decrease of approximately 14.7%[11]. - The company is focused on the development of a wearable device for non-invasive blood glucose monitoring, with a Generation 1 prototype already announced and work ongoing for Generation 2[23]. - Know Labs has developed a Generation 1 working prototype for a non-invasive blood glucose monitoring device, which is currently undergoing internal clinical testing[102]. - The company aims to achieve FDA clearance for its non-invasive blood glucose monitor, with ongoing studies comparing its technology to leading continuous glucose monitors showing a high degree of correlation[112]. - Recent studies have demonstrated the accuracy of Know Labs' Bio-RFID sensor technology, achieving a Mean Absolute Relative Difference (MARD) of 12.9% and 11.3% in quantifying blood glucose levels compared to established devices[117][118]. Capital and Financing - The company raised net proceeds of $5,472,791 from the sale of 28,000,000 shares of common stock at a price of $0.25 per share on September 29, 2023[165]. - The company has outstanding warrants that could potentially generate proceeds of up to $16,008,327 if exercised[27]. - The company is currently working on capital fundraising transactions to secure additional financing[26]. - The company believes it has enough cash to operate until at least June 30, 2024, but substantial doubt exists about its ability to continue as a going concern[25]. - The company has made staffing adjustments that have significantly reduced its monthly burn rate[24]. Stock and Equity - The weighted average shares of common stock outstanding increased from 48,187,339 in Q4 2022 to 81,094,007 in Q4 2023, an increase of approximately 68.3%[12]. - As of December 31, 2023, the company had 81,346,524 shares of common stock issued and outstanding, with various options and warrants outstanding that could dilute future earnings per share[42]. - The company issued 883,061 shares of common stock at a price of $0.25 per share, resulting in net proceeds of $203,105 after expenses[65]. - The company has a total of 28,220,473 stock options outstanding with an average exercise price of $0.907 as of December 31, 2023[75]. - The company recorded $699,246 in compensation expense related to stock options for the three months ended December 31, 2023[75]. Operational Efficiency - Total operating expenses decreased from $3,648,122 in Q4 2022 to $3,497,634 in Q4 2023, a reduction of about 4.1%[11]. - Selling, general and administrative expenses increased by $106,000 to $2,011,000 for the three months ended December 31, 2023, compared to $1,905,000 for the same period in 2022[158]. - The total depreciation expense for the three months ended December 31, 2023, was $18,724, a significant decrease of 81.9% compared to $103,160 for the same period in 2022[48]. - The company recognized total lease costs of $62,000 for the three months ended December 31, 2023, compared to $82,000 for the same period in 2022, reflecting a decrease of 24.4%[50]. - The company incurred expenses of $1,486,000 and $1,743,000 for development activities for the three months ended December 31, 2023, and 2022, respectively[132].

Know Labs, Inc. (NYSE:KNW) Q4 2023 Earnings Conference Call December 19, 2023 4:30 PM ET Company Participants Jordyn Hujar - Chief of Staff Ron Erickson - Chairman and Chief Executive Officer Pete Conley - Chief Financial Officer and Senior Vice President, Intellectual Property Operator Greetings. Welcome to the Know Labs Fourth Quarter Fiscal Year 2023 Earnings Conference Call. Please note, this conference call is being recorded. I will now turn the conference over to Jordyn Hujar, Know Labs' Chief of Staf ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to _____________ Commission File No. 001-37479 KNOW LABS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT For the transition period from _______ to ________ Commission File number 000-30262 KNOW LABS, INC. (Exact name of registrant as specified in charter) Nevada 90-0273142 (State or other jurisdiction of incorporation or organ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT For the transition period from _______ to ________ Commission File number 000-30262 KNOW LABS, INC. (Exact name of registrant as specified in charter) Nevada 90-0273142 (State or other jurisdiction of incorporation or orga ...

Know Labs, Inc. (NYSE:KNW) Q1 2023 Earnings Conference Call February 14, 2023 4:30 PM ET Company Participants Jordyn Hujar - Chief of Staff Ron Erickson - Chairman and Chief Executive Officer Pete Conley - Senior Vice President and Chief Financial Officer Operator Greetings, and welcome to the Know Labs Fiscal Year 2023 First Quarter Earnings Conference Call and Webcast. Please note, this conference call is being recorded. I will now turn the conference call over to Jordyn Hujar, Know Labs’ Chief of Staff. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT For the transition period from _______ to ________ Commission File number 000-30262 KNOW LABS, INC. (Exact name of registrant as specified in charter) Nevada 90-0273142 (State or other jurisdiction of incorporation or o ...

Technology Development - Know Labs, Inc. is focused on the development and commercialization of proprietary sensor technologies, specifically the Bio-RFID and ChromaID platforms, which utilize electromagnetic energy for material identification and measurement [27]. - The Bio-RFID technology has successfully demonstrated the ability to non-invasively measure blood glucose levels, addressing limitations of existing optical technologies [33]. - The company plans to market two versions of its non-invasive glucose monitoring device: the KnowU (desktop version) and the UBand (wearable version), both requiring FDA clearance [35]. - Internal laboratory testing has shown a high degree of correlation between Bio-RFID technology and leading continuous glucose monitors from Abbott Labs and DexCom [36]. - The company is also exploring additional analytes for monitoring through its devices, which will require separate FDA approvals [38]. - The ChromaID technology generates unique signatures from materials using light, enabling applications in authentication and verification [39]. - Bio-RFID technology enables real-time identification of a wide range of materials and analytes, enhancing clinical diagnostics and health monitoring [50]. - The Bio-RFID platform is expected to enter the continuous glucose monitoring market, with plans to expand into other clinical monitoring markets [59]. Regulatory and Compliance - The FDA regulates the company's medical diagnostic products, including KnowU and UBand, ensuring compliance with safety and effectiveness standards [63]. - The company believes its initial product is suitable for a de novo classification request with the FDA [79]. - Regulatory approvals are necessary for some products, and there is no assurance that such approvals will be granted, which could hinder revenue generation [130]. - International regulatory clearances are required for product sales outside the U.S., and failure to obtain these could harm business operations [131]. - The company is subject to increasingly stringent foreign governmental regulations for the manufacture and sale of medical devices, which may impact international sales [132]. Financial Performance - The company reported an accumulated deficit of $101,397,738 as of September 30, 2022, with net losses of $20,071,244 and $25,360,213 for the years ended September 30, 2022 and 2021, respectively [105]. - The company completed a public offering on September 20, 2022, selling 4,140,000 shares at $2.00 per share, generating total gross proceeds of $8,280,000 [102]. - The company anticipates needing additional financing to support technology development and ongoing operations, as it is currently operating at a loss [99]. - The potential proceeds from outstanding warrants could amount to up to $15,694,288, although there is no assurance these will be exercised [103]. - The company has limited insurance coverage, which may not cover significant claims, potentially impacting financial condition [115]. Intellectual Property - The company has been granted 27 patents and 19 design patents, with additional patents pending, supporting its intellectual property strategy [54]. - The company faces challenges in protecting its intellectual property, which could affect its competitive position and revenue [116]. Market Strategy - Know Labs, Inc. is building an internal sales and marketing team to prepare for the launch of its products and explore various market entry strategies [48]. - The competitive landscape includes large global technology companies, legacy providers, and new entrants, with Know Labs, Inc. believing its Bio-RFID technology offers a unique advantage in the market [49]. - The company aims to monetize its AI deep learning platform, exploring new applications to generate revenue for further development of its diagnostic technology [53]. Operational Challenges - The company is actively monitoring the impact of COVID-19 on its operations, which has caused supply chain delays and increased costs due to inflation [96]. - The company relies on external resources for engineering and product development, which could impact its ability to commercialize technology successfully [107]. - The company relies on key personnel, including its Chairman and CEO, and failure to retain them could adversely affect business operations [114]. - The company may face significant costs related to compliance with corporate governance and internal control requirements, which are expected to remain substantial [138]. - Cybersecurity risks pose a threat to the integrity and availability of sensitive information, necessitating ongoing investment in security measures [137]. Employee and Corporate Structure - The company has 16 full-time employees as of September 30, 2022, supplemented by consulting firms and contractors [62]. - The company has anti-takeover provisions in its bylaws designed to delay or prevent unsolicited acquisition attempts [212][215]. - The company has elected not to be governed by certain Nevada statutes that could limit third-party acquisitions of its stock [213][214]. Stock and Shareholder Information - As of September 30, 2022, the company had 48,156,062 shares of common stock issued and outstanding, with options and warrants potentially diluting future earnings per share [144]. - The company is authorized to issue up to 200,000,000 shares of common stock, which could lead to substantial dilution of existing stockholders' ownership [146]. - The market price of the company's common stock has been volatile, influenced by various market and industry factors, which may adversely affect stockholder investments [143]. - The company has never declared or paid cash dividends on its common stock and intends to retain all available funds for business operations [168].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT For the transition period from _______ to ________ Commission File number 000-30262 KNOW LABS, INC. (Exact name of registrant as specified in charter) (State or other jurisdiction of incorporation or organization) Nevada 90 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT For the transition period from _______ to ________ Commission File number 000-30262 KNOW LABS, INC. (Exact name of registrant as specified in charter) Nevada 90-0273142 (State or other jurisdiction of incorporation or orga ...